AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34538257
Drug: Ixekizumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (80 mg every 2 weeks or every 4 weeks)
Trial: 32703583
Drug: Initial intravenous
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial intravenous bolus of low-dose heparin (40 IU/kg)
Trial: 38942047
Drug: Namilumab 150
RxNorm normalized name: sarilumab
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Namilumab 150 mg
Trial: 32203971
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-specific treatment component)
Trial: 33320777
Drug: High-fructose corn
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fructose corn syrup
Trial: 35761841
Drug: PDL1/PD-1 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDL1/PD-1 inhibitors
Trial: 33478890
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of life (measured by Functional Assessment of Chronic Illness Therapy – Palliative Care)
Trial: 32327669
Drug: Micro-dosing application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-dosing application of 30.75 kg N ha-1 and 34.5 kg P2O5 ha-1 (N applied in three splits: 1/3 at sowing, 1/3 at emergence, and 1/3 at 45 days after emergence) at Aybra.
Trial: 32327669
Drug: Micro-dosing application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-dosing application of 20.5 kg N ha-1 and 23 kg P2O5 ha-1 (N applied in three splits: 1/3 at sowing, 1/3 at emergence, and 1/3 at 45 days after emergence) at Shumshiha-Lasta Lalibela.
Trial: 34417673
Drug: Anti-beta-1-adrenergic receptor
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-beta-1-adrenergic receptor antibodies (anti-β1-AR) in patients with CCM
Trial: 33218873
Drug: Brain Endurance
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain Endurance Training (BET) group completed concurrent cognitive tasks (2-back, Stroop) during 24 submaximal hand contractions sessions over 6 weeks.
Trial: 33218873
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group completed 24 submaximal hand contractions sessions over 6 weeks without concurrent cognitive tasks.
Trial: 33310604
Drug: Meditation program
RxNorm normalized name: Meditize
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meditation program involving daily use of the 'Muse' device for eight weeks
Trial: 35260292
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) by telephone
Trial: 32103319
Drug: Two whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two whole apples daily for 8 weeks
Trial: 34558768
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 or 25 mg)
Trial: 34240673
Drug: Menopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menopausal hormone therapy (MHT) - estradiol gel (1.5 mg/day) + oral micronized progesterone (100 mg/day)
Trial: 32434932
Drug: Ecologic Femi+
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ecologic Femi+ (EF+) vaginal capsule
Trial: 32434932
Drug: Gynophilus LP
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gynophilus LP (GynLP) vaginal tablet
Trial: 35105307
Drug: Topical local
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical local anesthesia with EMLA®
Trial: 35105307
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water injections without topical local anesthesia (Control group 1)
Trial: 35105307
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline 0.9% with topical local anesthesia (Control group 2)
Trial: 35105307
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline 0.9% without topical local anesthesia (Control group 3)
Trial: 33121861
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (preferred genre played during treatment)
Trial: 35125224
Drug: MAS-1 adjuvanted
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAS-1 adjuvanted IIV (0.3 mL, 9 µg per HA)
Trial: 35125224
Drug: MAS-1 adjuvanted
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAS-1 adjuvanted IIV (0.5 mL, 9 µg per HA)
Trial: 35125224
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose IIV (Fluzone HD, 60 µg per HA)
Trial: 34237655
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (SMO) 0.75, 1.25, 1.75 or 2.25 g t.i.d. for 12 weeks
Trial: 33799341
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment of the first dorsal interosseous muscle trigger points (MTrPs)
Trial: 34867113
Drug: Routine radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine radiotherapy and chemotherapy with routine nursing intervention
Trial: 32563606
Drug: Bivalent VLP
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent VLP vaccine with MPL
Trial: 32563606
Drug: Bivalent VLP
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent VLP vaccine without MPL
Trial: 32563606
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one dose)
Trial: 32563606
Drug: Bivalent VLP
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent VLP vaccine (one dose)
Trial: 32563606
Drug: Bivalent VLP
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent VLP vaccine (two doses)
Trial: 35452688
Drug: Oral propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propafenone
Trial: 34551681
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention group (oral presentation by CPCC and distribution of gift packages)
Trial: 32674126
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 800 mg on day 1 followed by 400 mg once daily for 6 days
Trial: 32153050
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine 10% spray
Trial: 32153050
Drug: Oral dapoxetine
RxNorm normalized name: duloxetine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dapoxetine 60 mg
Trial: 34463398
Drug: Laughter therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laughter therapy applied twice a week for 4 weeks
Trial: 35830482
Drug: Insulin correlation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin correlation with GIP and RQ
Trial: 34479761
Drug: Ketoprofen plaster
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen plaster 30 mg twice daily (n = 118)
Trial: 34479761
Drug: Diclofenac plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac plaster 15 mg once daily (n = 118)
Trial: 34479761
Drug: Ketoprofen plaster
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen plaster 30 mg twice daily
Trial: 34479761
Drug: Diclofenac plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac plaster 15 mg once daily
Trial: 34479761
Drug: Frequency of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency of rescue medication use
Trial: 34099584
Drug: High-fat load
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat load (150 g of fat at time 0)
Trial: 34099584
Drug: High-fat load
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat load with fructose (three doses of 50 g at 0, 2, and 4 hours)
Trial: 34099584
Drug: High-fat load
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat load with glucose (three doses of 50 g at 0, 2, and 4 hours)
Trial: 32985288
Drug: Urea cream
RxNorm normalized name: Amino Acid-Urea Cream
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea cream
Trial: 33952245
Drug: Group behavior
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group behavior therapy knowledge, attitude, and beliefs assessment
Trial: 33892671
Drug: EPIC program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPIC program (intervention with peer recovery supporter, family treatment drug court, medications for opioid use disorders, home-based parenting supports)
Trial: 33892671
Drug: Comparison groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison groups (Ohio START and treatment as usual)
Trial: 34884273
Drug: Scenar-On group
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scenar-On group (active treatment)
Trial: 34884273
Drug: Scenar-Off group
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scenar-Off group (sham treatment)
Trial: 34658139
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel containing 5% onion extract
Trial: 34658139
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel containing vitamin C (Control)
Trial: 34037282
Drug: palbociclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: palbociclib (125 mg/day, 3/1 schedule)–fulvestrant (500 mg, intramuscular injection)
Trial: 36231171
Drug: Pain Education
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Education Therapy (PET) group (n = 24)
Trial: 35986170
Drug: Traditional dysphagia
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional dysphagia therapy (TDT)
Trial: 35922794
Drug: Comparator formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator formulation of Ginkgo biloba extract
Trial: 32438401
Drug: Milk protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk protein (31 g, 26.2 g protein: 2.5 g leucine)
Trial: 32438401
Drug: Mycoprotein (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycoprotein (70 g, 31.5 g protein: 2.5 g leucine)
Trial: 34137291
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic prophylaxis (no AP)
Trial: 34137291
Drug: 2-year antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-year antibiotic prophylaxis (2-y AP)
Trial: 34137291
Drug: Lifetime antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifetime antibiotic prophylaxis (lifetime AP)
Trial: 34544205
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg once daily for 3 months
Trial: 33567400
Drug: Cenobamate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate treatment (100–400 mg/day)
Trial: 33567400
Drug: Cenobamate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate treatment (150–400 mg/day)
Trial: 33567400
Drug: Cenobamate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate treatment
Trial: 34293411
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl 2.5 mcg.mL‐1 (Group 1)
Trial: 34293411
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl 5 mcg.mL‐1 (Group 2)
Trial: 33058835
Drug: Testosterone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (150 mg)
Trial: 36281113
Drug: Low-to moderate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-to moderate intensity aerobic training (30 minutes daily)
Trial: 36281113
Drug: Conventional customized
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional customized physiotherapy (60 minutes daily)
Trial: 33625653
Drug: Pharmacist interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist interventions for drug-related problems (DRPs)
Trial: 33726810
Drug: Personalised hip
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised hip therapy (PHT)
Trial: 33726810
Drug: Personalised hip
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised hip therapy (PHT) to Hip arthroscopic surgery (HA)
Trial: 35968501
Drug: Sufentanil combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil combined with propofol (0.01‐0.03 μg/(kg·min) of sufentanil + 80‐100 μg/(kg·min) of propofol)
Trial: 35968501
Drug: Fentanyl (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (3 μg/(kg·h) of fentanyl + 80‐100 μg/(kg·min) of propofol)
Trial: 34548368
Drug: Clarithromycin 800
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 800 mg/day
Trial: 34548368
Drug: Clarithromycin 400
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 400 mg/day
Trial: 34548368
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without clarithromycin
Trial: 34215452
Drug: MenB‐FHbp booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenB‐FHbp booster dose administered 48 months after primary series
Trial: 34215452
Drug: MenB‐FHbp booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenB‐FHbp booster dose
Trial: 32379374
Drug: Intraderma injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraderma injection of 5-fluorouracil (5-FU)
Trial: 32713183
Drug: Prednisolone, 0.5
RxNorm normalized name: Moxifloxacin-Prednisolone, 0.5 g-1 g (1 g-1 g dose) ophthalmic suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone, 0.5 mg/kg (maximum dose 20 mg/day) qAM × 3 days postoperatively
Trial: 32713183
Drug: Non-steroid group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid group
Trial: 33459540
Drug: Modified-release betahistine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release betahistine (48 mg once daily)
Trial: 33459540
Drug: Betaserc (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaserc (24 mg twice daily)
Trial: 35869533
Drug: Empower-Autism programme
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Empower-Autism programme plus treatment-as-usual
Trial: 35869533
Drug: Usual local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual local post-diagnostic offer plus treatment-as-usual
Trial: 35482080
Drug: Alemtuzumab treatment
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab treatment
Trial: 33266039
Drug: Telephone-based parent
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based parent intervention (4 weekly 30-min support calls)
Trial: 36105267
Drug: START Together
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: START Together (experimental treatment)
Trial: 34688369
Drug: Mirtazapine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (titrated to 45 mg)
Trial: 33875799
Drug: 2.5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g/d of omega-3
Trial: 33875799
Drug: 1.25 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 g/d of omega-3
Trial: 33754455
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing strategies
Trial: 32667654
Drug: Rotigotine 2
RxNorm normalized name: ROTIGOTINE 2MG/24HRS PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine 2 mg transdermal patch for 1 week followed by a 4 mg patch for 23 weeks
Trial: 32667654
Drug: Placebo transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal patch for 24 weeks
Trial: 35484309
Drug: Lozenge
RxNorm normalized name: LOZENGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenge
Trial: 33371905
Drug: High-dose cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cholecalciferol (two 200,000 IU drinking vials at once on the day of inclusion)
Trial: 33371905
Drug: Standard-dose cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cholecalciferol (one 50,000 IU drinking vial on the day of inclusion)
Trial: 33371905
Drug: Standard-dose cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cholecalciferol
Trial: 34954857
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL) 5 mg iv with vitamin D 1000 IU/d
Trial: 34181084
Drug: Systemic analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic analgesia (S) with 1 gram of paracetamol and 2 mg/kg ketoprofen administered IV after skin closure
Trial: 33486139
Drug: Apomorphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine infusion (APO)
Trial: 616775801
Drug: GDF-15 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDF-15 group 1 (<1,200 ng/L)
Trial: 616775801
Drug: GDF-15 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDF-15 group 3 (>1,800 ng/L)
Trial: 36370185
Drug: Prolonged prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged prophylactic antibiotic therapy (PAT) group (Group B)
Trial: 36370185
Drug: No prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prolonged prophylactic antibiotic therapy group (Group A)
Trial: 35662546
Drug: CO2 vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 vaginal laser treatment
Trial: 32036258
Drug: Intrathecal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal ropivacaine + 5 μg dexmedetomidine (Group D)
Trial: 32051317
Drug: Platelet rich
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet rich plasma (PRP) injection
Trial: 35279741
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with apremilast and narrowband UVB
Trial: 35279741
Drug: Narrowband UVB
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Narrowband UVB monotherapy
Trial: 35677371
Drug: Orthodontics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontics plus implant anchorage
Trial: 36273083
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D3 (cholecalciferol) supplementation, weekly for six weeks
Trial: 32200813
Drug: Ranibizumab monthly
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab monthly treatment
Trial: 32200813
Drug: Bevacizumab monthly
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab monthly treatment
Trial: 32200813
Drug: Monthly treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly treatment
Trial: 32200813
Drug: As-needed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed treatment
Trial: 32200813
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from monthly to as-needed treatment